Testing DMD Gene Editing Inside the Body Brings Hope and Deadly Hazards

A repair crew inside muscle cells

Muscles need a shock-absorbing protein called dystrophin to stay intact during normal movement. In Duchenne muscular dystrophy (DMD), broken DNA stops this protein from working. Muscles slowly waste away as a result. To tackle this, scientists tested a direct fix: DMD gene editing carried out right inside living muscle cells, known as in vivo genome editing.

The team placed a DNA-cutting tool called hfCas12Max inside an AAV9 vector. Think of this vector as a tiny viral delivery van. It travels through the blood, enters muscle cells, and repairs the faulty gene directly on site.

What the tests showed

First, the team tested the treatment in animals. In mice with DMD, it cut the target DNA, partly brought back dystrophin, and improved muscle strength. In non-human primates, the tool edited the intended sites cleanly. The animals handled the dose well, with no life-threatening side effects under the test conditions.

Next came an open-label human trial. Muscle biopsies from human patients showed clear proof: the tool edited the DNA, and muscle cells began making dystrophin again. But the treatment soon hit a tragic wall. At a high dose of 1.0 × 10^14 vg/kg, one participant suffered a fatal immune response. Their immune system went into overdrive with severe complement activation, a rapid inflammation cascade that attacks foreign invaders. This triggered an intense chemical alarm shortly after the injection. The viral vans did their job, but sending too many at once proved lethal.

What we still do not know

The trial proves that editing tools can rewrite genes in living human muscle. Yet it also shows how narrow the safe dose range really is. We still do not know the exact balance between an effective dose and deadly toxicity. Researchers must now find drugs to calm the immune system, and they need to see if the rebuilt muscle stays healthy over time.